A phase III, randomized, multicenter, parallel-group clinical trial for examining the therapeutic equivalence between Fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg inhalation powder/GSK in patients with asthma - Therapeutic equivalence between two formulations of fluticasone and salmeterol

RESPIRENT Pharmaceuticals0 个研究点目标入组 451 人开始时间: 2018年7月25日最近更新: 2019年12月16日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 451

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•1.Male or female subjects (=12 years of age) of non-childbearing or of childbearing potential committed to consistent and correct use of an acceptable method of birth control.
•2.Patients diagnosed with asthma, as defined by the National Asthma Education and Prevention Program (NAEPP), at least 12 weeks prior to screening.
•3.Pre-bronchodilator FEV1 of =40% and =85% of the predicted value (for age =18 years), or =65% and =90% predicted normal value (for ages 12 to 17 years) during the screening visit and on the first day of treatment.
•4.Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and had = 10 pack-years of historical use.
•5.=12% and 200 mL reversibility of FEV1 within 30 minutes following 400 mcg salbutamol (4 puffs) inhalation (pMDI). This may be demonstrated at the Screening Visit or this test may be repeated on a different day if the patient fails the first attempt anytime in the period leading up to Visit 2 (randomization); If reversibility is not demonstrated up to Visit 2 then patients may be permitted to enter the study with historical evidence of reversibility that was performed within 2 years prior to Visit 1 and patients should be stable on their chronic asthma treatment regimen for at least 4 weeks prior to enrolment.
•6.Patients who are able to discontinue their asthma medications (inhaled corticosteroids and long-acting ß agonists) during the run-in period and for remainder of the study, according to investigator’s judgement.
•7.Patients who are able to replace current short-acting ß agonists (SABAs) with salbutamol inhaler for use as needed for the duration of the study (subjects should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits).
•8.Patients who are able to continue treatment with theophylline or montelucast without a significant adjustment of dosage, formulation, dosing interval for the duration of the study, and judged able by the investigator to withhold them for the specified minimum time intervals prior to each patient visit: 1) montelucast 36 hours 2) short-acting forms of theophylline 12 hours, 3) twice-a-day controlled-release forms of theophylline 24 hours, 4) once-a-day controlled-release forms of theophylline 36 hours.
•9.Patients who are able to understand the requirements of the clinical trial and to agree to return for the required follow-up visits.
•10.Willing to provide voluntary written informed consent and data protection declaration (and in the case of a minor their parent/guardian was able to give) before any clinical trial related procedure is performed
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 51
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 300
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 100

排除标准

•1.Life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnoea; respiratory arrest or hypoxic seizures, asthma related syncopal episode(s), or hospitalizations within the past year or during the run-in period.
•2.Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia.
•3.Historical or current evidence of significant hematologic, hepatic neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease
•exacerbated during the study.
•4.Hypersensitivity to any sympathomimetic drug (e.g., salmeterol or albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy.
•5.History of hypersensitivity to lactose
•6.Medication(s) with the potential to affect the course of asthma or to interact with sympathomimetic amines, e.g.: ß-blockers, oral decongestants, benzodiazepines, digitalis, phenothiazines, polycyclic antidepressants, monoamine oxidase inhibitors.
•7.Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks prior to the screening visit or during the run-in period.
•8.Asthma exacerbations within 6 weeks prior to the screening visit or during the run-in period.
•9.Use of oral or parenteral corticosteroids within 4 weeks prior to Screening visit (Visit 1)
•10.Factors (e.g., infirmity, disability or geographic location) that the investigator felt would likely limit the patient's compliance with the study protocol or scheduled clinic visits.
•11.Female Subjects who are pregnant or breastfeeding.
•12.Women of child-bearing age that are not surgically incapable of pregnancy and are not willing to use an acceptable method of birth control.
•13.Current participation or not yet completed period of at least 30 days since ending other investigational device or drug trial(s).
•14.Unwillingness or inability to comply with the clinical trial procedures;
•15.Unwillingness to consent to storage, saving and transmission of pseudonymous medical data for clinical trial reasons;
•16.Who are legally incapacitated;
•17.Who are legally detained in an official institute

研究者

发起方

RESPIRENT Pharmaceuticals

相似试验

进行中（未招募）

1 期

This study will evaluate and confirm that a new formulation of Fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals is therapeutically equivalent to the marketed formulation Advair DISKUS® 100/50 mcg inhalation powder/GSK in patients with asthmaAsthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitationMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 21.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders

EUCTR2022-002977-27-GRRespirent Pharmaceuticals Co. Ltd451

进行中（未招募）

1 期

This study will evaluate and confirm that a new formulation of Fluticasone propionate 100 mcg/blister oral inhalation powder/RespirentPharmaceuticals is therapeutically equivalent to the marketed formulation Flovent DISKUS® 100 mcg/blister oral inhalation powder/GSK in patients with asthma

EUCTR2020-002977-84-GRRESPIRENT Pharmaceuticals451

进行中（未招募）

1 期

A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegalyAcromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular disease is the main reason for morbidity and increased mortality.MedDRA version: 12.1Level: LLTClassification code 10000599Term: Acromegaly

EUCTR2009-016722-13-NOovartis Pharma Services AG198

进行中（未招募）

1 期

EUCTR2009-016722-13-ITOVARTIS FARMA186

进行中（未招募）

1 期

efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegalyAcromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular disease is the main reason for morbidity and increased mortality.MedDRA version: 17.1Level: PTClassification code 10000599Term: AcromegalySystem Organ Class: 10014698 - Endocrine disorders

EUCTR2009-016722-13-DEovartis Pharma Services AG219